Patent · US Active

Antibodies to PMEL17 and conjugates thereof

US11779649B2 · kind B2 · utility

0Cited by

4References

55Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Matthew Burger · Belmont, US
Joseph Anthony D'Alessio · Boston, US
Tony Fleming · Stow, US
Vivek Rauniyar · Cambridge, US
Eusebio Manchado Robles · Basel, CH
Christian Carsten Silvester KUNZ · Munich, DE
Markus Waldhuber · Munich, DE

Key dates

Filing date	Dec 18, 2019
Grant date	Oct 10, 2023
Priority date	—
Expiry date	May 10, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/56
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates comprising antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The application also discloses methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.